Bibliography
- NARUSE I, OHMORI T, AO Y et Antitumor activity of the selective epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) Iressa (ZD1839) in an EGFR-expressing multidrug-resistant cell line in vitro and in vivo. bit .j Cancer (2002) 98(2):310–315.
- LEVIN M, D'SOUZA N, CASTANER J: Iressa. Drugs Fut. (2002) 27(4):339–345.
- MUHSIN M, GRAHAM J, KIRKPATRICK P: Fresh from the pipeline - gefitinib. Nat. Rev Drug Discov. (2003) 2(7):515–516.
- NAKAGAWA K, TAMURA T, NEGORO S et al.: Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (Iressa, ZD1839) in Japanese patients with solid malignant tumors. Ann. Oncol. (2003) 14(6):922–930.
- NATALE RB, ZARETSKY SL: ZD1839 (IressaTm): What's in it for the patient? Oncologist (2002) 7\(Supp1.4):25–30.
- NORMAN P: ZD-1839 (AstraZeneca). Cur. Opia Investig. Drugs (2001) 2(3):428–434.
- RANSON M, MANSOOR W JAYSON G: ZD1839 (IRESSA): a selective EGFR-TK inhibitor. Expert Rev Anticancer Ther. (2002) 2(2):161–168.
- AstraZeneca's Iressa "Oncology Compound of Year, Marketletter, 2004, Aug 30.
- CONNELL RD: The 2-oxindole chemotype and patent activity inspired by the SU5416 franchise. Exp. Opia Ther. Patents (2003) 13:737–749.
- CARLOMAGNO F, VITAGLIANO D, GUIDA T et al: ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. (2002) 62(24):7284–7290.
- SMITH JK, MAMOON NM, DUHE RJ: Emerging roles of targeted small molecule protein-tyrosine kinase inhibitors in cancer therapy. Oncology Res. (2004) 14(4-5):175–225.
- BLAKEY DC, ASHTON SE, WESTWOOD FR, WALKER M, RYAN AJ: ZD6126: A novel small molecule vascular targeting agent. hit. I Radiation Oncology Biol., Phys. (2002) 54(5):1497–1502.
- SIEMANN DW, CHAPLIN DJ, HORSMAN MR: Vascular-targeting therapies for treatment of malignant disease. Cancer (2004) 100(12):2491–2499.
- •An example of an excellent review.
- CIARDIELLO F: Epidermal growth factor receptor tyrosine kinase inhibitors as anticancer agents. Drugs (2000) 60\(Supp1.1):25–32.